fda drug safety communication naion semaglutide 2025 November 2025 Drug Safety: Recalls for Compounded Semaglutide, Generic Synthroid; Safety updates for Lamictal, Kineret, Miebo eye drops, Zoladex; Microneedling Injuries, more Frontiers | Unmasking counterfeit semaglutide:
Description
L.HallM
The key distinction is between occasional timing shifts and chronic inconsistency
The next drug on fast track at FDA to be imminently approved is tirzepatide (Mounjaro) following its approval for diabetes in May 2022
A 2025 preformulation study published in the Journal of Peptide Science examined semaglutide stability across multiple temperature conditions
Insurance implications: Most plans wont cover off-label use
The FDA classifies semaglutide as Category C in pregnancy, meaning animal studies have shown adverse fetal effects, but human data remains limited
